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Overexpression of the Mammalian Target of Rapamycin
A Novel Biomarker for Poor Survival in Resected Early Stage
Non-small Cell Lung Cancer
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Mattia Barbareschi, MD, Bernard V. North, PhD,¶ and Michael J. Seckl, MD, PhD*
Introduction: The best hope of cure for patients with non-small cell
lung cancer (NSCLC) is surgical resection. However, even in stage
IA patients, 30% die within 5 years. Further improvements in
survival require a biomarker(s), which defines the subset of these
patients destined to do badly so that they could be targeted for
additional therapies. Here, we investigate whether the immunohis-
tochemical expression of a key kinase implicated in lung cancer
biology, the mammalian target of rapamycin (mTOR) can predict
survival outcome in patients with early stage resected NSCLC.
Materials and Methods: One hundred thirty-four patients with
resected early stage (IA–IIB) NSCLC were pathologically reviewed
centrally before staining for mTOR. Multiple variables including
age, sex, stage, angioinvasion, lymph node status, and mTOR
staining were assessed by univariate and multivariate analyses.
Results: Stage (p  0.044), lymph node status (p  0.049),
angioinvasion (p  0.017), and mTOR staining (p  0.007) were
significant univariate predictors of poor survival. However, only
angioinvasion (p  0.016) and mTOR staining (p  0.046) re-
mained significant after multivariate analysis. Moreover, mTOR
staining was the only variable to predict poor outcome in patients
who either had negative lymph nodes (p  0.016) or were stage IA
(p  0.0016).
Conclusions: The mTOR staining provides a new biomarker for
poor outcome in early stage NSCLC and could enable resected stage
IA patients to be selected for novel therapies possibly with an
mTOR inhibitor.
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Lung cancer is the biggest cancer killer accounting for moredeaths than breast, prostate, and colon cancers combined.1
Non-small cell lung cancer (NSCLC) is responsible for 80% of
cases. Most affected patients present with inoperable locally
advanced (stage IIIB) or metastatic (stage IV) disease, which is
nearly always incurable. The best chance of achieving long-term
survival is in early stage disease when complete surgical resec-
tion is possible. However, even in resected stage IA patients
30% succumb from their disease within 5 years.2
To further improve the outcome of early stage (IA–
IIIA) resected patients, several studies have examined the
benefits of postoperative adjuvant chemo- and/or radiother-
apy. Current data indicate that only stage II–IIIA patients gain
additional benefit from adjuvant chemotherapy.3–6 However,
stage IA and stage IB patients without lymph node involvement
fail to demonstrate a clear and consistent survival advantage
with this treatment.4,7 Consequently, there has been considerable
interest in defining new biomarkers, which could accurately
identify, for example, the 30% of stage IA patients who relapse
and die of lung cancer after surgery. Such individuals could then
be targeted for novel therapies.
Vascular or lymphatic vessel invasion have both been
suggested as potential markers for poor outcome in stage IA
patients but results have been controversial and inconsis-
tent.2,8–10 Other predictive factors such as sex, performance
status, and sublobar resections have also given variable re-
sults.11 More recently, there has been considerable interest in
new molecular biomarkers such as the excision repair cross-
complementation group 1 protein but its role in predicting
outcome in early stage resected patients is promising but not
yet clear.12–14 Genomic strategies have also showed promis-
ing results15 using gene-expression profiles. Interestingly, we
have recently found that the mammalian target of rapamycin
(mTOR) is overexpressed in lung cancer cells compared with
normal lung epithelial cells.16 This kinase plays a central role
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in regulating cell growth, proliferation, and survival down-
stream of multiple growth factors, which have been impli-
cated in lung cancer biology.16–18 The mTOR acts as a point
of convergence integrating a plethora of signaling pathways,
such as the phosphotidylinositol 3-kinase/AKT pathway,
which responds to growth factors and nutritional status.
Moreover, mTOR inhibitors are currently undergoing clinical
trials in advanced NSCLC.
Here, we investigate whether the immunohistochemical
expression of mTOR can predict survival outcome in early
resected NSCLC cases.
MATERIALS AND METHODS
Patients
A series of 134 patients with primary operable NSCLC
(stage IA–IIB) were investigated from July 1987 to March
2000 at Perugia University Hospital, Italy. At surgery, an
average of nine lymph nodes (range 1–22) were sampled per
patient. Surgical specimens were routinely processed and
classified according to the World Health Organization crite-
ria.19 Histopathological data on tumor type, grade, lymph
node status, stage, and angioinvasion together with clinical
data including age, sex, performance status, time to relapse,
and overall survival were routinely recorded prospectively in
a database as previously published.20 The study was approved
by the local institution review board.
Tissue Microarray Construction
Lung cancer tissue microarrays (TMA) were prepared
as previously described.21 Briefly, 1 mm cores were obtained
from the most representative areas of the tumors then re-
embedded in microarray blocks. Each case was sampled three
times.
Immunostaining and Immunohistochemistry
Scoring for mTOR
The mTOR immunoreactivity was evaluated on TMA
sections using the mTOR rabbit monoclonal antibody (Cell
signaling, Danvers, MA) in a modification of the antigen
retrieval technique of Shi et al.22 Briefly, the sections were
rehydrated in graded alcohols, heated in a microwave oven at
900W for 20 minutes in citrate buffer at pH6. They were
cooled at room temperature before immunostaining. The
mTOR monoclonal antibody was used at 1:50 dilution for 1
hour at room temperature and then processed with Polymer-
HRP Kit (BioGenex, San Ramon CA) with Diaminobenzi-
dine development and Mayer hematoxylin counterstaining.
An mTOR positive small cell lung cancer cell line (H510)
cytoblock was used as a positive external control. Negative
controls were obtained by omitting the primary antibody,
using competing peptide used to raise the primary antibody
and by staining H510 cells in which mTOR had been selec-
tively knocked down by RNAi (Dharmacon, Fisher Scientific,
Loughborough, Leicestershire, UK).
A semiquantitative immunohistochemical score (IHS)
was used including assessment of both the intensity of stain-
ing and the percentage of positive cells. For the intensity, a
score of 0 to 3, corresponding to negative, weak, moderate,
and strong positivity, was recorded. The range of possible
scores was thus 0 to 300. IHS and similar semiquantitative
scoring systems have been successfully used for other TMA
evaluations.23
Each core was scored individually. Three cores were
evaluated from each tumor, and the mean of the three read-
ings was calculated. If one core was uninformative, the score
applied was the mean of the remaining two cores. All immu-
nohistochemical staining was independently evaluated by two
pathologists (F.M., M.B.) without knowledge of the clinical
data. The interobserver discrepancy was limited to 3% of
cases. These cases were reviewed at the double head micro-
scope, and an agreement was reached.
TABLE 1. Clinicopathological Characteristics of 134
Patients with Early NSCLC
Patient Characteristics No. of Cases (%)
Age
65 57 (43)
65 77 (57)
Gender
Male 117 (88)
Female 17 (12)
Stage
1a 34 (24)
1b 57 (41)
2a 13 (9)
2b 30 (26)
Lymph node
Positive 34 (25)
Negative 100 (75)
Histology
Adenocarcinoma 41 (30)
Squamous 56 (42)
Large cell 26 (19
Broncheoalveolar 9 (7)
Mixed 1 (1)
Neuroendocrine 1 (1)
Surgical intervention
Lobectomy 112 (84)
Pneumonectomy 22 (16)
Grade
1 8 (6)
2 43 (31)
3 82 (60)
4 1 (3)
Dead
Yes 91 (68)
No 43 (32)
mTOR staining
Positive 73 (55)
Negative 61 (45)
Angioinvasion
Positive 27 (28)
Negative 69 (72)
NSCLC, non-small cell lung cancer; mTOR, mammalian target of rapamycin.
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Statistical Analyses
Statistical analyses were performed using SPSS for
Windows (version 15) and the R Project version 7.0. Percent-
ages were rounded to the nearest whole integer. The Kaplan-
Meier method was used to determine survival.24 The overall
survival was defined as the time (in months) from the date of
the primary treatment to the time of death. To define the
optimum mTOR IHS a Martingale graph plotting excess
deaths against mTOR value for lung cancer. The optimal
cutoff is identified as the point where the curve cuts the x axis
and the strength of the estimates cutoff is indicated by the
slope of the increase in excess deaths with increasing mTOR
value25 was performed (See Figure, Supplemental Digital
Content 1, http://links.lww.com/JTO/A14). We assessed the
univariate effect of each variable on survival by log-rank test
(this statistical test has no hazard ratio [HR]) for categorical
predictors or the univariate Cox model for continuous pre-
dictors. Variables, which were significant univariately (stage,
mTOR, and angioinvasion) were candidates for a multi-
variate Cox model. Selection of predictors in this final
model of 0.05 for entry into the model and p  0.1 for
removal of insignificant predictors. These are the default
cutoffs in SPSS 15. The fit of the multivariate and univar-
iate Cox models was confirmed by the supremum test of
Martingale-based residuals.
RESULTS
The mean age of the population was 65.6 years (range
31–86) and most (88%) were men (Table 1). All NSCLC
tumor types with stages IA to IIB were present in the series,
and at the time of primary diagnosis, 100 (74%) patients were
lymph node negative and 34 (26%) had positive lymph nodes.
All the patients had a Karnofsky performance status of at
least 90%. The median follow-up was 4.4 years (range
0–16.8 years), and a total of 91 (68%) patients died in the
study period. Importantly, the overall survival of this group of
patients stratified by stage (Figure 1) is in keeping with other
published series.26,27
We next examined mTOR staining in the tissue arrays
established from the resected tumors. Immunostaining of
mTOR was mostly cytoplasmic (Figure 2) and was found in
0 to 100% of the tumor cells with a varying intensity (grades
1–3). There were no significant relationships between mTOR
and clinical characteristics apart from an increase in mTOR
FIGURE 1. Kaplan-Meier survival plot of survival by stage of
134 patients with non-small cell lung cancer (NSCLC).
FIGURE 2. Panel A, example of negative mam-
malian target of rapamycin (mTOR) staining in
NSCLC; Panel B, weak mTOR staining; Panel C,
moderate mTOR staining; and Panel D, strong
mTOR staining. Bar, 100 m.
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staining in those patients with positive lymph nodes (data not
shown). The significance of mTOR on survival was assessed
by a univariate Cox model to be p  0.055. To define the
optimum mTOR IHS, a Martingale graph plotting excess
deaths against mTOR value for lung cancer was performed.
The optimal cutoff is identified as the point where the curve
cuts the x axis, and the strength of the estimates cutoff is
indicated by the slope of the increase in excess deaths with
increasing mTOR value for lung cancer survival25 was per-
formed. A similar approach using a cutoff value has been used
in the past to establish a 10% staining cutoff for Her2/neu in
breast cancer28 and specifically using a Martingdale plot in
prostate cancer.29 The best cutoff for mTOR staining in NSCLC
was provided at an IHS of 30 (See Figure, Supplemental Digital
Content 1, http://links.lww.com/JTO/A14) where 73 (55%) of
the patients stained positive for mTOR (Table 1).
Table 2 shows that as expected, stage (p 0.044 by log
rank; HR  1.76, 95% confidence interval [CI]  0.992–
3.12), lymph node status (p  0.049 by log rank; HR  1.59,
95% CI  1.0–2.56), and angioinvasion (p  0.017; HR 
1.91, 95% CI 1.12–3.31) were significantly associated with
poor survival in agreement with previously published find-
ings.8,10 Strikingly, Table 2 and Figure 3 demonstrate that
mTOR staining was also significantly associated with poor
survival (p  0.007 [log rank], HR  1.77, 95% CI 
1.16–2.71). Moreover, only mTOR positive staining (p 
0.046 [log rank], HR  1.66, 95% CI  1.01–2.74) and
angioinvasion (p  0.016 [log rank], HR  1.95, 95%
CI  1.13–3.35) remained significant as predictors of
overall survival on multivariate analysis.
We next investigated whether mTOR staining might
predict poor survival in patients who were lymph node
negative as this group currently has no clear prognostic
factor. Figure 4A shows that the survival of lymph node
negative patients whose primary tumors were mTOR positive
was significantly lower (p  0.016 [log rank], HR  1.83,
95% CI  1.11–3.05). In contrast, angioinvasion and other
factors were nonpredictive (data not shown). These results
suggest that the survival of patients with stage IA disease who
are all lymph node negative might be most influenced by
mTOR staining. Indeed, Figure 4B demonstrates that mTOR
staining was a highly significant prognostic marker for this
group of patients. The median survival was 2.1 years in the
mTOR positive verses 5.6 years in the mTOR negative
FIGURE 3. Kaplan-Meier survival plot of survival of 134 pa-
tients with NSCLC for mTOR positive and mTOR negative.
TABLE 2. Univariate and Multivariate Analysis of Patient Characteristics for Survival
Patient Characteristics
Univariate
Analysis
p Value HR 95% CI
Multivariate
Analysis
p Value HR 95% CI
Age 0.445 0.990 0.77–1.28 NA
Gender 0.44 0.87 0.68–1.13 NA
Stage
1b vs 1a 0.044 0.57 0.37–0.86 NS
2a vs 1a 1.00 0.72–1.39
2b vs 1a 1.33 0.79–2.24
Lymph node 0.049 1.59 1.0–2.56 NA
Histology
Large cell vs squamous 0.767 1.31 0.55–3.09 NA
Adeno vs squamous 1.24 0.49–3.15
Alveolar vs squamous 1.02 0.41–2.50
Surgical intervention 0.125 0.656 0.38–1.13 NA
Grade
2 vs 1 0.320 0.57 0.07–4.77 NA
3 vs 1 0.40 0.05–3.01
4 vs 1 0.62 0.09–4.53
mTOR staining 0.007 1.77 1.17–2.73 0.046 1.66 1.01–2.74
Angioinvasion 0.017 1.91 1.12–3.31 0.016 1.95 1.13–3.35
Univariate analysis performed using log-rank test therefore no hazard ratio listed (except for age).
HR, hazard ratio; 95% CI, 95% confidence interval; NA, not applicable; NS, not significant.
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patients (p  0.0016 [log rank], HR  4.38, 95% CI 
1.62–11.83). Taken together, a positive mTOR IHS of more
than 30 seems to predict poor outcome in stage IA and lymph
node negative patients with early stage NSCLC.
CONCLUSIONS
Here, we show for the first time that mTOR immuno-
histochemical staining predicts poor outcome in early stage
NSCLC. More specifically, it seems to identify poor outcome
in lymph node negative and stage IA patients where previ-
ously other markers such as angioinvasion have failed to
consistently yield prognostic benefit. Obviously, the data
presented here just represents a single patient cohort, and it
would be important to know whether this could be repro-
duced in larger independent series. Potti et al.15 in 2006 using
a multigene-expression profile predicted recurrence for pa-
tients significantly better than clinical prognostic factors in
early NSCLC. Recently, immunohistochemical staining for
L-type amino acid transporter I has also been shown to
provide prognostic information in resected NSCLC within a
Japanese patient population.30 The expression/activity of this
transporter seems to be closely linked to mTOR.31 It is
therefore tempting to speculate that the expression of these
two molecules in clinical material may be linked and that our
findings may not be isolated to one patient cohort. In addition,
it is noteworthy that others have recently shown increased
mTOR staining is linked to adverse prognosis in breast and
biliary cancers.23,32 However, an article published recently33
showed the opposite—i.e high expression of mTOR is linked
to better outcomes in early NSCLC. This would seem counter
intuitive with respect to known mTOR biology and to mTOR
expression and prognosis in other cancers mentioned earlier.
Possible reasons for these differences include differing im-
munohistochemical techniques and having more women in
the cohort tested in the more recent study.
The phosphatidylinositol 3-kinase/Akt/mTOR signal-
ing pathway is frequently deregulated in cancers and repre-
sents an attractive target for anticancer therapy.17 Sirolimus
and its analogues Temsirolimus, Everolimus, and Deforoli-
mus are specific small molecule inhibitors of mTOR and
some of these agents are now being examined as novel
therapies for lung cancer. Our results suggest that patients
with early stage NSCLC who are mTOR positive have a
worse prognosis. It is tempting to speculate that such mTOR
positive patients might benefit from an mTOR inhibitor
and/or chemotherapy. However, we recognize that our find-
ings are preliminary and a further validation study is now
urgently required and if confirmed, clinical trials are needed.
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